Lead Sponsor

Boehringer Ingelheim

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Written informed consent prior to participation
•2. Female and male patients = 40 years of age
•3. Patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD) and requiring long-acting dual bronchodilation (LAMA + LABA) treatment according to approved Spiolto® Respimat® SmPC and COPD GOLD guideline recommendation

•1. Patients with contraindications according to Spiolto® Respimat® SmPC
•2. Patients who have been treated with a Long-acting beta2 adrenoceptor agonist\\Long-acting muscarinic antagonist (LABA/LAMA) combination (free and fixed dose) in the previous 6 weeks.
•3. Patients continuing Long-acting beta2 adrenoceptor agonist Inhalative Corticosteroids (LABA-iCS) treatment should not be additionally treated with Spiolto® Respimat® in order to avoid a double dosing of long-acting beta-agonists
•4. Patients for whom further follow-up is not possible at the enrolling site during the planned study period of approx. 6 weeks
•5. Pregnancy and lactation
•6. Patients currently listed for lung transplantation

Related studies

NCT06712563 · Pulmonary Disease, Chronic Obstructive

NCT07518472 · Pulmonary Disease, Chronic Obstructive (COPD)

NCT06831994 · Asthma Bronchiale, Breast Neoplasms, and more

NCT06283004 · Pulmonary Disease, Chronic Obstructive

NCT05730088 · Pulmonary Disease, Chronic Obstructive

Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)